Miltefosine Zentaris.
Copyright policy )Miltefosine Zentaris.
Zentaris (formerly Asta Medica) has developed and launched miltefosine, a phospholipid derivative, in various European countries [173324], [254947] and in Brazil in 1997 [332428], [366795] as a treatment for breast cancer. As of January 2002, phase III trials for treatment of leishmaniaisis were ongoing [435767]. In February 1999, Lehman Brothers predicted miltefosine would be launched for treatment of leishmaniasis in 2002, with peak sales expected in 2010 [319225].
- Novartis (Switzerland) Switzerland
Clinical Trials as Topic, Structure-Activity Relationship, Phosphorylcholine, Administration, Oral, Animals, Humans, Leishmaniasis, Visceral, Trypanocidal Agents, Drug Administration Schedule
Clinical Trials as Topic, Structure-Activity Relationship, Phosphorylcholine, Administration, Oral, Animals, Humans, Leishmaniasis, Visceral, Trypanocidal Agents, Drug Administration Schedule
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!